ECSP20080995A - Derivados de tetrahidrotienopiridina n–sustituidos y sus usos - Google Patents

Derivados de tetrahidrotienopiridina n–sustituidos y sus usos

Info

Publication number
ECSP20080995A
ECSP20080995A ECSENADI202080995A ECDI202080995A ECSP20080995A EC SP20080995 A ECSP20080995 A EC SP20080995A EC SENADI202080995 A ECSENADI202080995 A EC SENADI202080995A EC DI202080995 A ECDI202080995 A EC DI202080995A EC SP20080995 A ECSP20080995 A EC SP20080995A
Authority
EC
Ecuador
Prior art keywords
substituted
tetrahydrothienopyridine derivatives
derivatives
substituted tetrahydrothienopyridine
useful
Prior art date
Application number
ECSENADI202080995A
Other languages
English (en)
Inventor
Wei Lin Sandra Sim
Fumiaki Yokokawa
Hui Quan Yeo
Bin Zou
Gang Wang
Bryan Ks Yeung
Cyrille Kounde
Oliver Simon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67841114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP20080995(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP20080995A publication Critical patent/ECSP20080995A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un compuesto de Fórmula (I) que ha demostrado ser útil para el tratamiento de una enfermedad causada por una infección viral:(I) en donde R1, R2, R3, A, L, m, n, p y q son como se definen en la presente memoria.
ECSENADI202080995A 2018-06-19 2020-12-15 Derivados de tetrahidrotienopiridina n–sustituidos y sus usos ECSP20080995A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19

Publications (1)

Publication Number Publication Date
ECSP20080995A true ECSP20080995A (es) 2021-02-26

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202080995A ECSP20080995A (es) 2018-06-19 2020-12-15 Derivados de tetrahidrotienopiridina n–sustituidos y sus usos

Country Status (24)

Country Link
US (3) US12012417B2 (es)
EP (2) EP3810613B1 (es)
JP (1) JP7328260B2 (es)
KR (1) KR102835904B1 (es)
CN (1) CN112313237A (es)
AU (1) AU2019291488B2 (es)
BR (1) BR112020025696A2 (es)
CA (1) CA3100957A1 (es)
CL (1) CL2020003248A1 (es)
CR (1) CR20200618A (es)
CU (1) CU20200100A7 (es)
EA (1) EA202190046A1 (es)
EC (1) ECSP20080995A (es)
ES (2) ES2941946T3 (es)
IL (1) IL279441B2 (es)
JO (1) JOP20200326A1 (es)
MA (1) MA52976A (es)
MX (1) MX2020013852A (es)
MY (1) MY201990A (es)
PE (1) PE20210097A1 (es)
PH (1) PH12020552185A1 (es)
SA (1) SA520420809B1 (es)
SG (1) SG11202012625PA (es)
WO (1) WO2019244047A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
EA202190046A1 (ru) 2018-06-19 2021-03-24 Новартис Аг N-замещенные производные тетрагидротиенопиридина и их применение
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment
WO2025238553A1 (en) 2024-05-14 2025-11-20 Novartis Ag Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-2-(4-sulfamoylphenyl)acetamide for use in treating or preventing a dengue virus disease or disorder
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US498178A (en) 1893-05-23 William valentine leonard
US54472A (en) 1866-05-01 Improved blacking-brush
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US4656A (en) 1846-07-24 Improvement in potato-plows
US5807A (en) 1848-09-26 Brake fob cabs
US6344A (en) 1849-04-17 Driving-bobbin
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
DE60236428D1 (de) 2001-05-21 2010-07-01 Monsanto Technology Llc Etheramin-tenside enthaltende pestizidkonzentrate
US20030232994A1 (en) 2001-10-04 2003-12-18 Shao-Po Lu Bicyclic thiophene derivatives and combinatorial libraries thereof
WO2004024066A2 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
PL1753512T3 (pl) 2004-05-28 2009-03-31 4Sc Ag Tetrahydropirydotiofeny
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
CA2596202A1 (en) 2005-02-09 2006-08-17 Altana Pharma Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
US7741488B2 (en) 2005-02-11 2010-06-22 4Sc Ag Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer
CN101218224B (zh) 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
US7763728B2 (en) 2005-05-25 2010-07-27 4Sc Ag Tetrahydropyridothiophenes
US7714136B2 (en) 2005-05-25 2010-05-11 4Sc Ag Tetrahydropyridothiophenes
EP1942110A4 (en) 2005-09-08 2010-08-04 Zhejiang Huahai Pharm Co Ltd PREPARATION OF CLOPIDOGREL AND ITS ANALOG METHYLTETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS
AU2007285735A1 (en) 2006-08-16 2008-02-21 4Cs Ag Tetrahydrobenzothiophene derivatives
CA2660794A1 (en) 2006-08-16 2008-02-21 4Sc Ag Ntetrahydropyridothiophene derivatives for the treatment of cancer
WO2008067222A1 (en) 2006-11-28 2008-06-05 Kalypsys, Inc. Heterocyclic modulators of tgr5
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2011008988A (es) * 2009-02-27 2011-12-16 Siga Technologies Inc Derivados de tienopiridina para el tratamiento y prevencion de infecciones por el virus del dengue.
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
JP5701655B2 (ja) * 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
AP2014007595A0 (en) 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
CN108689987A (zh) * 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
SI3630724T1 (sl) * 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
EP3663299B1 (en) 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
EA202190046A1 (ru) 2018-06-19 2021-03-24 Новартис Аг N-замещенные производные тетрагидротиенопиридина и их применение

Also Published As

Publication number Publication date
EP3810613B1 (en) 2023-01-11
CU20200100A7 (es) 2021-08-06
SA520420809B1 (ar) 2022-08-17
MA52976A (fr) 2021-04-28
EP3810613A1 (en) 2021-04-28
EP4169925A2 (en) 2023-04-26
JP2021529159A (ja) 2021-10-28
US12012417B2 (en) 2024-06-18
PE20210097A1 (es) 2021-01-12
US20260070920A1 (en) 2026-03-12
CR20200618A (es) 2021-01-21
CA3100957A1 (en) 2019-12-26
EP4169925A3 (en) 2023-06-14
KR20210022645A (ko) 2021-03-03
ES2941946T3 (es) 2023-05-26
PH12020552185A1 (en) 2021-06-07
US12331060B2 (en) 2025-06-17
ES3062606T3 (en) 2026-04-13
KR102835904B1 (ko) 2025-07-22
SG11202012625PA (en) 2021-01-28
US20220073535A1 (en) 2022-03-10
EA202190046A1 (ru) 2021-03-24
MY201990A (en) 2024-03-27
JP7328260B2 (ja) 2023-08-16
JOP20200326A1 (ar) 2020-12-14
BR112020025696A2 (pt) 2021-03-16
IL279441A (en) 2021-01-31
US20240352030A1 (en) 2024-10-24
CN112313237A (zh) 2021-02-02
IL279441B2 (en) 2023-06-01
AU2019291488A1 (en) 2021-02-04
CL2020003248A1 (es) 2021-07-09
WO2019244047A1 (en) 2019-12-26
AU2019291488B2 (en) 2022-02-24
EP4169925B1 (en) 2025-11-19
MX2020013852A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
UY35155A (es) Derivados cíclicos de nucleósidos y usos de los mismos
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
ECSP15018618A (es) Inhibidores no nucleósidos de la transcriptasa inversa
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
CR20170285A (es) Compuestos de triazolopirimidina y usos de los mismos
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2018003311A (es) Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CR20170035A (es) Compuestos de imidazopiridazina
MX2022015151A (es) Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
DOP2013000051A (es) Compuestos heterociclico y sus usos
CR20180615A (es) Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina
UY37641A (es) Compuestos de isoxazol carboxamida y usos de los mismos
CU24716B1 (es) FORMA POLIMÓRFICA ESTABLE DE 6-FLUORO-9-METIL-9H-ß-CARBOLINA
UY35627A (es) Derivados de 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hidroxiprop-1-il)-4-metoxi-3-(fenilsulfonilmetil)tetrahidrofuran-2-il)acetaldehido y procedimiento para su preparacion.